| 1 |
Polyák H, Galla Z, Nánási N, Cseh EK, Rajda C, Veres G, Spekker E, Szabó Á, Klivényi P, Tanaka M, Vécsei L. The Tryptophan-Kynurenine Metabolic System Is Suppressed in Cuprizone-Induced Model of Demyelination Simulating Progressive Multiple Sclerosis. Biomedicines 2023;11:945. [PMID: 36979924 DOI: 10.3390/biomedicines11030945] [Reference Citation Analysis]
|
| 2 |
Brum M, Nieberler M, Kehrwald C, Knopf K, Brunkhorst-Kanaan N, Etyemez S, Allers KA, Bittner RA, Slattery DA, McNeill RV, Reif A, Kittel-Schneider S. Phase-and disorder-specific differences in peripheral metabolites of the kynurenine pathway in major depression, bipolar affective disorder and schizophrenia. World J Biol Psychiatry 2023;:1-14. [PMID: 36648064 DOI: 10.1080/15622975.2023.2169348] [Reference Citation Analysis]
|
| 3 |
Sapienza J, Spangaro M, Guillemin GJ, Comai S, Bosia M. Importance of the dysregulation of the kynurenine pathway on cognition in schizophrenia: a systematic review of clinical studies. Eur Arch Psychiatry Clin Neurosci 2022. [PMID: 36460745 DOI: 10.1007/s00406-022-01519-0] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 4 |
Yilmaz NS, Sen B, Karadag RF, Aslan S, Ekmekci Ertek I, Bozkurt A, Cicek S, Bolu A, Ucar H, Kocak C, Cevik C, Bukan N. A kynurenine pathway enzyme aminocarboxymuconate-semialdehyde decarboxylase may be involved in treatment-resistant depression, and baseline inflammation status of patients predicts treatment response: a pilot study. J Neural Transm (Vienna) 2022;129:1513-26. [PMID: 36334154 DOI: 10.1007/s00702-022-02553-x] [Reference Citation Analysis]
|
| 5 |
Almulla AF, Thipakorn Y, Vasupanrajit A, Abo Algon AA, Tunvirachaisakul C, Hashim Aljanabi AA, Oxenkrug G, Al-Hakeim HK, Maes M. The tryptophan catabolite or kynurenine pathway in major depressive and bipolar disorder: A systematic review and meta-analysis. Brain Behav Immun Health 2022;26:100537. [PMID: 36339964 DOI: 10.1016/j.bbih.2022.100537] [Reference Citation Analysis]
|
| 6 |
Mu J, Liu X, Dong Y, Fang Y, Qiu S, Zhang F, Liu K. Peripheral interleukin-6-associated microglial QUIN elevation in basolateral amygdala contributed to cognitive dysfunction in a mouse model of postoperative delirium. Front Med 2022;9. [DOI: 10.3389/fmed.2022.998397] [Reference Citation Analysis]
|
| 7 |
Almulla AF, Vasupanrajit A, Tunvirachaisakul C, Al-Hakeim HK, Solmi M, Verkerk R, Maes M. The tryptophan catabolite or kynurenine pathway in schizophrenia: meta-analysis reveals dissociations between central, serum, and plasma compartments. Mol Psychiatry 2022;27:3679-91. [PMID: 35422466 DOI: 10.1038/s41380-022-01552-4] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 15.0] [Reference Citation Analysis]
|
| 8 |
Ding W, Wu F, Zhou S, Li H, Wang R, Ning Y. Increased plasma level of kynurenic acid in drug-free patients with first-episode schizophrenia compared to patients with chronic schizophrenia and healthy controls: preliminary data. Nord J Psychiatry 2022;76:451-6. [PMID: 34928781 DOI: 10.1080/08039488.2021.1992647] [Reference Citation Analysis]
|
| 9 |
Pedroso I, Kumbhare SV, Joshi B, Saravanan SK, Mongad DS, Singh-Rambiritch S, Uday T, Muthukumar KM, Irudayanathan C, Reddy-Sinha C, Dulai PS, Sinha R, Almonacid DE. Mental Health Symptom Reduction Using Digital Therapeutics Care Informed by Genomic SNPs and Gut Microbiome Signatures. J Pers Med 2022;12. [PMID: 36013186 DOI: 10.3390/jpm12081237] [Reference Citation Analysis]
|
| 10 |
Almulla AF, Thipakorn Y, Vasupanrajit A, Abo Algon AA, Tunvirachaisakul C, Hashim Aljanabi AA, Oxenkrug G, Al-hakeim HK, Maes M. The tryptophan catabolite or kynurenine pathway in major depressive and bipolar disorder: a systematic review and meta-analysis.. [DOI: 10.1101/2022.06.13.22276359] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 11 |
Pedroso I, Kumbhare SV, Joshi B, Saravanan SK, Mongod DS, Singh-rambiritch S, Uday T, Muthukumar KM, Irudayanathan C, Reddy-sinha C, Dulai PS, Sinha R, Almonacid DE. Mental Health Symptom Reduction Using Digital Therapeutics Care Informed by Genomic SNPs and Gut Microbiome Signatures.. [DOI: 10.1101/2022.04.27.22273901] [Reference Citation Analysis]
|
| 12 |
Morrens M, Overloop C, Coppens V, Loots E, Van Den Noortgate M, Vandenameele S, Leboyer M, De Picker L. The relationship between immune and cognitive dysfunction in mood and psychotic disorder: a systematic review and a meta-analysis. Mol Psychiatry 2022;27:3237-46. [PMID: 35484245 DOI: 10.1038/s41380-022-01582-y] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 7.0] [Reference Citation Analysis]
|
| 13 |
Menon V, Balasubramanian I, Rajkumar R. Association between markers of oxidative stress and cognitive functioning in schizophrenia. Ann Indian Psychiatry 2022;6:304. [DOI: 10.4103/aip.aip_174_22] [Reference Citation Analysis]
|
| 14 |
Almulla AF, Vasupanrajit A, Tunvirachaisakul C, Al-hakeim HK, Solmi M, Verkerk R, Maes M. The tryptophan catabolite or kynurenine pathway in schizophrenia: meta-analysis reveals dissociations between central, serum and plasma compartments.. [DOI: 10.1101/2021.12.16.21267905] [Reference Citation Analysis]
|
| 15 |
Postolache TT, Medoff DR, Brown CH, Fang LJ, Upadhyaya SK, Lowry CA, Miller M, Kreyenbuhl JA. Lipophilic vs. hydrophilic statins and psychiatric hospitalizations and emergency room visits in US Veterans with schizophrenia and bipolar disorder. Pteridines 2021;32:48-69. [PMID: 34887622 DOI: 10.1515/pteridines-2020-0028] [Reference Citation Analysis]
|
| 16 |
Leclercq S, Schwarz M, Delzenne NM, Stärkel P, de Timary P. Alterations of kynurenine pathway in alcohol use disorder and abstinence: a link with gut microbiota, peripheral inflammation and psychological symptoms. Transl Psychiatry 2021;11:503. [PMID: 34599147 DOI: 10.1038/s41398-021-01610-5] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 8.5] [Reference Citation Analysis]
|
| 17 |
Klaus F, Guetter K, Schlegel R, Spiller TR, Seifritz E, Cathomas F, Kaiser S. Common and disorder-specific upregulation of the inflammatory markers TRAIL and CCL20 in depression and schizophrenia. Sci Rep 2021;11:19204. [PMID: 34584171 DOI: 10.1038/s41598-021-98769-0] [Reference Citation Analysis]
|
| 18 |
Cathomas F, Klaus F, Guetter K, Seifritz E, Hartmann-riemer MN, Tobler PN, Kaiser S, Kaliuzhna M. Associations Between Negative Symptoms and Effort Discounting in Patients With Schizophrenia and Major Depressive Disorder. Schizophrenia Bulletin Open 2021;2. [DOI: 10.1093/schizbullopen/sgab022] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
